YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimil...
AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and...
Eli Lilly and Company announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (d...
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced the compa...
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to ...
Fujirebio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/&beta...
Shanghai Ark Biopharmaceutical announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic...
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (tra...
Invisalign® Palatal Expanders offer doctors a removeable, safe, and clinically effective alternative to traditional palatal expanders. With Invi...
Cariflex Pte. Ltd. (Cariflex), the global market leader in polyisoprene rubber latex for medical-end markets and wholly owned subsidiary of DL Chem...
Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study A First-in-class oral small molecule modulating immune cell metabolism vi...
Biocom California, the association representing the California life science industry, and KoreaBIO, a life science trade association which seeks to solid...
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectu...
LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. y announced an exclusive license and commercialization agreement for Lotus to commercial...
© 2025 Biopharma Boardroom. All Rights Reserved.
